Cargando…

Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts

Detalles Bibliográficos
Autores principales:	Dragani, Matteo, Petiti, Jessica, Rege-Cambrin, Giovanna, Gottardi, Enrico, Daraio, Filomena, Caocci, Giovanni, Aguzzi, Chiara, Crisà, Elena, Andreani, Giacomo, Caciolli, Francesca, Fava, Carmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2020
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485467/ https://www.ncbi.nlm.nih.gov/pubmed/32952977 http://dx.doi.org/10.4084/MJHID.2020.066

Ejemplares similares

Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 Transcripts
por: Petiti, Jessica, et al.
Publicado: (2020)

Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start?
por: Bochicchio, Maria Teresa, et al.
Publicado: (2021)

Genetic Screening for Potential New Targets in Chronic Myeloid Leukemia Based on Drosophila Transgenic for Human BCR-ABL1
por: Lo Iacono, Marco, et al.
Publicado: (2021)

Alignment of Qx100/Qx200 Droplet Digital (Bio-Rad) and QuantStudio 3D (Thermofisher) Digital PCR for Quantification of BCR-ABL1 in Ph+ Chronic Myeloid Leukemia
por: Fava, Carmen, et al.
Publicado: (2021)

Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR
por: Jovanovski, Aleksandar, et al.
Publicado: (2020)

Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH
por: Rosso, Valentina, et al.
Publicado: (2015)

Pure red cell aplasia and amegakaryocytic thrombocytopenia in thymoma: The uncharted territory
por: Dragani, Matteo, et al.
Publicado: (2020)

Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?
por: Cilloni, Daniela, et al.
Publicado: (2019)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
por: Serpa, Mariana, et al.
Publicado: (2010)

Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells
por: Rosso, Valentina, et al.
Publicado: (2019)

Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase
por: Fokoloros, Christos, et al.
Publicado: (2022)

Atypical chronic myeloid leukemia BCR-ABL 1 negative: A case report and literature review
por: Belkhair, Jihane, et al.
Publicado: (2019)

Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation
por: Okabe, Seiichi, et al.
Publicado: (2015)

Acute Megakaryoblastic Leukemia Harboring a Subclone Expressing BCR-ABL1 Fusion Gene Product
por: Kashima, Emiko, et al.
Publicado: (2021)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia
por: Petiti, Jessica, et al.
Publicado: (2020)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Potent antiproliferative effect of fatty‐acid derivative AIC‐47 on leukemic mice harboring BCR‐ABL mutation
por: Shinohara, Haruka, et al.
Publicado: (2019)

Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2021)

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
por: Massimino, Michele, et al.
Publicado: (2021)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

The choice of first-line Chronic Myelogenous Leukemia treatment
por: Fava, Carmen, et al.
Publicado: (2015)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias
por: Stella, Stefania, et al.
Publicado: (2019)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
por: Marcé, Sílvia, et al.
Publicado: (2021)

P685: LATE PHASE BCR-ABL DECLINE PREDICTS THE DURATION OF TKI (IMATINIB) FOR SUCCESSFUL TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA.
por: R, Chethan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iokji90bk0m31kb73lc52e5l7h